SCHEMBL2368043

SCHEMBL2368043

Cc1cccc(CNc2nc(NCCO)nc3sc(C)c(-c4ccccc4)c23)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.45
FGFR1 P11362 1/20 0.37
ESR1 P03372 1/20 0.37
ALDH1A1 P00352 5/20 0.37
KDM4E B2RXH2 4/20 0.37
HPGD P15428 3/20 0.37
MAPK1 P28482 2/20 0.37
CASP1 P29466 1/20 0.37
RAB9A P51151 1/20 0.37
CASP7 P55210 1/20 0.37
HSD17B10 Q99714 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
KCNH2 Q12809 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
CDK1 P06493 3/20 0.36
GAA P10253 2/20 0.36
CDK2 P24941 2/20 0.36
CDK5 Q00535 2/20 0.36
CCNB2 O95067 1/20 0.36
CCNE2 O96020 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368734 0.92 PRKCI (0.39) PRKCIALDH1A1MAPK1CDK1GAA
SCHEMBL2368953 0.88 KCNH2 (0.48) PRKCIMAPK1KCNH2SMN1; SMN2CDK2
SCHEMBL2369221 0.85 PRKCI (0.43) PRKCIFGFR1ESR1ALDH1A1KDM4E
SCHEMBL2369432 0.85 GAA (0.36) ALDH1A1KDM4EMAPK1SMN1; SMN2CDK1
SCHEMBL2369270 0.84 PDCD1 (0.39) ALDH1A1KDM4EHPGDMAPK1HSD17B10
SCHEMBL2369288 0.83 ESR1 (0.48) ESR1ALDH1A1KDM4EHPGDMAPK1
SCHEMBL5807363 0.83 PRKCI (0.38) PRKCIFGFR1ALDH1A1KDM4EHPGD
SCHEMBL2368489 0.83 PRKCI (0.41) PRKCIFGFR1ESR1ALDH1A1KDM4E
SCHEMBL2368869 0.82 PRKCI (0.43) PRKCIFGFR1ESR1ALDH1A1KDM4E
SCHEMBL2368909 0.81 KCNA5 (0.44) PRKCIMAPK1KCNH2SMN1; SMN2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 PRKCI 2326/4885FGFR1 1333/4885ESR1 4494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.